Novo Nordisk Charts a New Strategic Course Amid Market Shifts

Novo Nordisk cuts Wegovy & Ozempic prices by 50%, partners on $2.1B oral drug deal, and faces a clinical setback for CagriSema in a pivotal week.

The Danish pharmaceutical giant Novo Nordisk is undergoing a significant strategic transformation. A series of recent announcements—spanning aggressive price cuts, a clinical trial setback, and a major new partnership—highlight the company's efforts to navigate a rapidly evolving market for its blockbuster drugs.

A Multi-Billion Dollar Bet on Oral Medications

On February 25, Novo Nordisk moved to diversify its future pipeline by entering a collaboration with Vivtex Corporation. The partnership, valued at up to $2.1 billion, focuses on developing oral biological medicines for obesity, diabetes, and related conditions.

Vivtex, a Boston-based biotech startup co-founded by MIT professor Robert Langer, will license selected oral delivery technologies to Novo Nordisk. The deal includes upfront payments, research funding, and potential milestone payments totaling the $2.1 billion figure, plus tiered royalties on future product sales. Novo Nordisk will assume responsibility for development, regulatory approval, manufacturing, and commercialization following the research and formulation selection phases. This initiative aims to make biological drugs, which are currently only available as injections due to poor gastrointestinal absorption, accessible in pill form.

Significant Price Reductions Announced for Key Drugs

Just one day prior, on February 24, the company revealed plans to substantially lower the list prices for its weight-loss drug Wegovy and the diabetes medications Ozempic and Rybelsus, effective 2027. The new uniform monthly wholesale price will be set at $675.

This represents a dramatic 50% reduction from Wegovy's current price of $1,349. For Ozempic and Rybelsus, the cut amounts to a 34% decrease from $1,028. The timing aligns with new, lower Medicare prices negotiated with the U.S. government under the Inflation Reduction Act, which set the price for these three drugs at $274 per month.

While insured patients with deductibles or high out-of-pocket costs are positioned to benefit most, Novo Nordisk had already reduced direct prices for cash-paying customers. The company currently offers its medications directly for between $149 and $499 monthly, depending on the product and dosage.

Clinical Setback for Pipeline Candidate CagriSema

The week's developments began with a piece of disappointing clinical news. On February 23, Novo Nordisk disclosed late-stage trial results showing that participants using its successor drug CagriSema lost less weight than those on Eli Lilly's competing treatment, Zepbound. The announcement triggered a 16% drop in the company's share price.

Analysts have since expressed growing doubts about CagriSema's commercial potential, a product intended to bolster future revenue. Company leadership, however, maintains an optimistic outlook. In a subsequent conference call, executives emphasized that the drug could achieve the highest weight reduction of all available agents following its anticipated approval in late 2026 and market launch in 2027. They pointed to ongoing studies designed to demonstrate its full potential.

Market Dynamics Intensify Competitive Pressure

These events underscore a structural shift in the GLP-1 drug market. Despite being the first to bring a GLP-1 weight-loss medication to market, Novo Nordisk's market share has fallen to approximately 40%. Eli Lilly is now estimated to control about 60% of the segment.

The combined 2025 revenue for Ozempic and Wegovy reached roughly $32 billion, accounting for nearly 67% of Novo Nordisk's total sales. This heavy reliance on two products highlights the strategic importance of the Vivtex partnership and broader pipeline diversification efforts.

Competition is further intensifying from telemedicine providers selling compounded versions of weight-loss drugs at lower prices. Novo Nordisk recently filed a lawsuit against Hims & Hers, a move viewed as a warning to other competitors in the space.

Financial Forecast and Future Drivers

Earlier in the month, Novo Nordisk provided a 2026 forecast projecting a sales and profit decline of between 5% and 13%. Analysts from FactSet anticipate a decrease of around 8% compared to 2025. In an interview with CNBC, CEO Mike Doustdar stated, "People should expect it to go down before it goes back up." He pins long-term recovery hopes on new medications, the Wegovy tablet, and higher sales volumes.

The oral version of Wegovy is considered a key future growth driver and has reportedly had a strong start. Tablet forms eliminate the need for injections, offering patients greater flexibility. The company's annual general meeting on March 26, 2026, is expected to provide further clarity on its strategic direction moving forward.